Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Sara Harrysson"'
Autor:
Kenny A Rodriguez-Wallberg, Jonas Bergh, Antonis Valachis, Per Frisk, Theodoros Foukakis, Per Ljungman, Sandra Eloranta, Hanna Pauline Nilsson, Johan Malmros, Christina Linder Stragliotto, Erika Isaksson Friman, Barbro Linderholm, Anne Andersson, Sara Harrysson, Lovisa Vennström, Helena Mörse
Publikováno v:
BMJ Open, Vol 13, Iss 12 (2023)
Background Gonadotropin-releasing hormone agonists (GnRHa) cotreatment used to transiently suppress ovarian function during chemotherapy to prevent ovarian damage and preserve female fertility is used globally but efficacy is debated. Most clinical s
Externí odkaz:
https://doaj.org/article/ba5924fc50df467589005f382b3a4808
Autor:
Kristina Sonnevi, Maria Ljungqvist, Jóel Kristinn Jóelsson, Sara Harrysson, Tove Wästerlid, Per Bernell, Björn Engelbrekt Wahlin
Publikováno v:
eJHaem, Vol 2, Iss 4, Pp 774-784 (2021)
Abstract Patients with high‐risk aggressive B‐cell lymphoma exhibit poor survival after R‐CHOP. More intensive regimens yield higher rates of remission but also of complication. We investigated all 401 patients
Externí odkaz:
https://doaj.org/article/5185da9e7f6e45189ee1703f58593a70
Autor:
Sara Harrysson, Sandra Eloranta, Sara Ekberg, Gunilla Enblad, Mats Jerkeman, Bjorn E. Wahlin, Per-Ola Andersson, Karin E. Smedby
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract We performed a national population-based study of all patients diagnosed with diffuse large B-cell lymphoma (DLBCL) in Sweden in 2007–2014 to assess treatment intent and risk of relapsed/refractory disease, including central nervous system
Externí odkaz:
https://doaj.org/article/a1305d2d921849bf9a6993bb265176df
Autor:
Amineh Ghaderi, Amir Hossein Daneshmanesh, Ali Moshfegh, Parviz Kokhaei, Jan Vågberg, Johan Schultz, Thomas Olin, Sara Harrysson, Karin E Smedby, Elias Drakos, Georgios Z. Rassidakis, Anders Österborg, Håkan Mellstedt, Mohammad Hojjat-Farsangi
Publikováno v:
Biomedicines, Vol 8, Iss 6, p 170 (2020)
The receptor tyrosine kinase ROR1 is absent in most normal adult tissues, but overexpressed in several malignancies. In this study, we explored clinical and functional inhibitory aspects of ROR1 in diffuse large B-cell lymphoma (DLBCL). ROR1 expressi
Externí odkaz:
https://doaj.org/article/d36a9e454ef446bc87fdc28c52d68ddd
Autor:
Sara Ekberg, Michael Crowther, Sara Harrysson, Mats Jerkeman, Karin E. Smedby, Sandra Eloranta
Publikováno v:
British Journal of Cancer. 127:1642-1649
Background Achieving lasting remission for at least 2 years is a good indicator for favourable prognosis long term after Diffuse large B-cell lymphoma (DLBCL). The aim of this study was to provide real-world probabilities, useful in risk communicatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e615979e4aaa434cabfef365bafba2d4
https://doi.org/10.1038/s41416-022-01931-2
https://doi.org/10.1038/s41416-022-01931-2
Autor:
Kristina Sonnevi, Christopher M. Melén, Karin E. Smedby, Sara Harrysson, Tove Wästerlid, Björn E. Wahlin
Publikováno v:
British Journal of Haematology. 192:75-81
Diffuse large B-cell lymphoma (DLBCL) incidence rises with increasing age. Rituximab-anthracycline-based regimens offer a potential cure but also risks of adverse events, especially in the elderly. Using Swedish registers, we conducted a nationwide,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd12fa3a6e94ab8c0cf3f13170968bda
https://doi.org/10.1111/bjh.16737
https://doi.org/10.1111/bjh.16737
Autor:
Tove Wästerlid, Jóel Kristinn Jóelsson, Björn E. Wahlin, Per Bernell, Sara Harrysson, Kristina Sonnevi, Maria Ljungqvist
Publikováno v:
EJHaem. 2(4)
Patients with high-risk aggressive B-cell lymphoma exhibit poor survival after R-CHOP. More intensive regimens yield higher rates of remission but also of complication. We investigated all 401 patients 70 years with high-risk (age-adjusted [aa] inter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::004d8d0dff2bf3f3dcc14a811f682c0a
https://pubmed.ncbi.nlm.nih.gov/35845206
https://pubmed.ncbi.nlm.nih.gov/35845206
Autor:
Sara Ekberg, Tomas Jernberg, Sandra Eloranta, Per-Ola Andersson, Karolina Szummer, Sara Harrysson, Mats Jerkeman, Karin Ekstroem Smedby
Publikováno v:
Journal of internal medicineReferences. 290(5)
Background: The outcome for diffuse large B-cell lymphoma (DLBCL) patients has improved with the immunochemotherapy combination R-CHOP. An increased rate of heart failure is well documented following this treatment, whereas incidence and outcome of o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df0b75e72f6b9f512b00c160527a891e
https://pubmed.ncbi.nlm.nih.gov/34110046
https://pubmed.ncbi.nlm.nih.gov/34110046
Autor:
Sara Ekberg, Gunilla Enblad, Mats Jerkeman, Karin E. Smedby, Björn E. Wahlin, Sara Harrysson, Sandra Eloranta, Per-Ola Andersson
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Vol 11, Iss 1, Pp 1-10 (2021)
Blood Cancer Journal, Vol 11, Iss 1, Pp 1-10 (2021)
We performed a national population-based study of all patients diagnosed with diffuse large B-cell lymphoma (DLBCL) in Sweden in 2007–2014 to assess treatment intent and risk of relapsed/refractory disease, including central nervous system (CNS) re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bf4eac31f8152175dbf0b2d967219cf
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-435207
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-435207
Autor:
Therese M.-L. Andersson, Tove Wästerlid, Mats Jerkeman, Sandra Eloranta, Sara Ekberg, Per-Ola Andersson, Gunilla Enblad, Sara Harrysson, Karin E. Smedby
Patients with diffuse large B-cell lymphoma (DLBCL) who fail to complete planned treatment with R-CHOP due to toxicity are sparsely described. We investigated the extent of failure to complete treatment (six cycles or more, or three cycles + RT for p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::581e140a5b507c679cad027b951fe499
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-423834
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-423834